Procedures
In the treatment group, patients orally received 1250 mg nelfinavir (625 mg per tablet, provided by Agouron Pharmaceuticals, LLC, a subsidiary of Pfizer Inc.) every 12 h for 14 days, or according to the investigator’s judgment, the patient can continue to take nelfinavir until the efficacy endpoint is reached or the investigator judges that the patient cannot benefit from nelfinavir. Patients assigned to the control group received only basic treatment.